Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zalcitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.62 |
| ▸ | ALB | P02768 | 3/20 | 0.62 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.62 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.62 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.54 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | POLG | P54098 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zalcitabine SCHEMBL21100417 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL10380711 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL598496 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL3715526 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL9194365 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL3598 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL12149465 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL3235525 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL27555151 | 0.99 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL29277683 | 0.99 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6040297-A | A THERAPEUTIC AGENTS TREATING TUMORS AND RETROVIRAL INFECTIONS INCLUDING HIV INFECTIONS | BIOSEARCH ITALIA, S.P.A. (IT) | 2000-03-21 | — | — | US | claimed |
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| EP-4015005-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ModernaTX, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3492109-B1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2020-03-04 | — | — | EP | disclosed |
| EP-3492109-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| WO-2017201585-A1 | MODULATORS OF DUX4 FOR REGULATION OF MUSCLE FUNCTION | GENEA IP HOLDINGS PTY LTD (AU) | 2017-11-30 | — | — | WO | disclosed |
| EP-3028707-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | Ophthotech Corporation (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7378402-B2 | 4-Amino-1-((2R,3S,4S,5R)-5-azido-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one; hepatitis C virus. | ROCHE PALO ALTO LLC (US) | 2008-05-27 | — | — | US | disclosed |
| US-6040297-A | A THERAPEUTIC AGENTS TREATING TUMORS AND RETROVIRAL INFECTIONS INCLUDING HIV INFECTIONS | BIOSEARCH ITALIA, S.P.A. (IT) | 2000-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | LMNA 3149/4885PDE3A 3539/4885ALB 2193/4885 |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | PNP, TYMP, NTPCR | LMNA 1477/4885PDE3A 617/4885ALB 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.